Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Weerasak, Nawarawong"'
Autor:
Ulrich Jaeger, Marek Trneny, Helen Melzer, Michael Praxmarer, Weerasak Nawarawong, Dina Ben Yehuda, David Goldstein, Bilijana Mihaljevic, Osman Ilhan, Veronika Ballova, Michael Hedenus, Liang-Tsai Hsiao, Wing-Yan Au, Sonja Burgstaller, Gerhard Weidinger, Felix Keil, Christian Dittrich, Cathrin Skrabs, Anton Klingler, Andreas Chott, Michael A. Fridrik, Richard Greil
Publikováno v:
Haematologica, Vol 100, Iss 7 (2015)
We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338) or observation (n=345).
Externí odkaz:
https://doaj.org/article/e4ed4d06af08447a81949f26f4ec0900
Autor:
Brian G.M. Durie, Juan Ramon Navarro, Gislaine Oliveira Duarte, Chor Sang Chim, Guillermo J. Ruiz-Argüelles, Wenming Chen, Rosane Bittencourt, Kihyun Kim, Jae Hoon Lee, David Gómez-Almaguer, Edvan de Queiroz Crusoe, Angelo Maiolino, Dorotea Fantl, Guillermo Conte, Shang Y.I. Huang, Gracia Martinez, Kazuyuki Shimizu, Wee Joo Chng, Weerasak Nawarawong, Vania Hungria
Publikováno v:
Annals of Hematology. 98:941-949
In previous observational studies, we have separately characterized patients with multiple myeloma (MM) both from Latin America (LA) and from Asia. Here, we analyze these two datasets jointly, in order to assess the overall survival (OS) in these two
Autor:
Bernardo Garichochea, Judit Demeter, Yuankai Shi, Umberto Vitolo, Enrica Morra, Margarida Marques, Miklos Egyed, Toshiki Uchida, Árpád Illés, Kenichi Ishizawa, Cristina Ligia Cebotaru, Ashis Mukhopadhyay, Masafumi Taniwaki, Sung-Soo Yoon, Cristina-Ligia Truica, Cheol Won Suh, Irina Lysenko, Naokuni Uike, Huaqing Wang, Achiel Van Hoof, Maryna Kyselyova, Osmanov Ea, Andrew Belch, Alexy Kuzmin, Caballero Gabarrón, Steven Van Steenweghen, Sergio Cancelado, Olga Samoilova, Kensei Tobinai, Kiyoshi Ando, Susumu Nakahara, Tatiana Scheider, Massimo Federico, Dmitry Udovitsa, Xiaoyan Ke, Yurii Lorie, Tatsu Shimoyama, Weerasak Nawarawong, Sebastian Grosicki, Gregor Verhoef, Nuriet Khuageva, Suporn Chuncharune, Fritz Offner, Albert Oriol Rocafiguera, Charles Farber, Ernst Späth-Schwalbe, Juliana Pereira, Ting Liu, Lee-Yung Shih, Steven Le Gouill, Miklos Udvardy, Richard Greil, Carmen Cao, Tomohiro Kinoshita, Horia Bumbea, Yasuhito Terui, Eva Gonzalez-Barca, Irina Bulavina, Peter Hu, Francisco Javier Capote, Olga Serduk, Akihiro Tomita, Ilseung Choi, Mahmut Gumus, Udomsak Bunworasate, Adriana Teixeira, Vladimir Merkulov, Yeow Tee Goh, Tadeusz Robak, Huiqiang Huang, Jie Jin, Cristina Ileana Burcoveanu, Halyna Pylypenko, Joaquín Díaz, Herlander Marques, Zoltán Gasztonyi, Vijay Rao Phooshkooru, Gayane Tumyan, Maike De Wit, Ali Khojasteh, Marcelo Capra, Vladimir Lima, Dai Maruyama, Viacheslav Pavlov, Georg Heß, Carmino Antonio De Souza, Zhao Wang, Iryna Kryachok, Amel Mezlini, Galvez Cardenas, Marina Golubeva, Lyudmila Kuzina, Patricia Santi, Remy Gressin, Balkis Meddeb, Xiaonan Hong, David Belada, Bernard De Prijck, Jan Maciej Zaucha, Jiri Mayer, Michinori Ogura, Rumiko Okamoto, Dolores, Irit Avivi, Mario Ojeda-Uribe, Grigoriy B Rekhtman, Jun Zhu, Reyes Arranz, Polina Kaplan, André Bosly, Ann Van De Velde, Kenny Mauricio, Yuri Dunaev, Anatoly Golenkov, Oleg Gladkov, Yoshiharu Maeda, Franco Cavalli, Dina Ben Yehuda, Michele Baccarani, Markus Raderer, Razvan Stoia, Carlos Appiani, Zvenyslava Masliak, Zita Borbenyi, Guiseppe Rossi, Julia Alexeeva, Johannes Drach, Kateryna Vilchevskaya, Georgii Manikhas, Jan Novák, Noppadol Siritanaratkul, Zhixiang Shen, Alexander Suvorov, Michael Crump, Pierre Zachee, Ofer Shpilberg, Sepideh Nemat, Mitsutoshi Kurosawa, Sreejith Nair, Bulent Undar, Govind Babu, Kudrat Abdulkadryrov, Adriana Sheliga
Publikováno v:
The Lancet Oncology. 19:1449-1458
Summary Background In the LYM-3002 study, the efficacy and safety of frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) and rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were c
Autor:
Weerasak Nawarawong, Daryl Tan, Shang-Yi Huang, Pankaj Malhotra, Chor Sang Chim, Wenming Chen, Kihyun Kim, Wee Joo Chng, Jian Hou, Jae Hoon Lee, Brian G.M. Durie, Kazuyuki Shimizu, Kenshi Suzuki, Lalit Kumar
Publikováno v:
Leukemia & Lymphoma. 59:2305-2317
Predicated on our improved understanding of the disease biology, we have seen remarkable advances in the management of multiple myeloma over the past few years. Recently approved drugs have radically transformed the treatment paradigm and improved su
Autor:
Pimjai Niparuck, Suporn Chuncharunee, Chittima Sirijerachai, Arnuparp Lekhakula, Noppadol Siritanaratanakul, Naree Warnnissorn, Wasana Kanoksil, Nisa Makruasi, Thamathorn Assanasen, Kannadit Prayongratana, Charin Ya-In, Lalita Norasetthada, Somchai Wongkhantee, Tontanai Numbenjapon, Weerasak Nawarawong, Peerapon Wong, Paisarn Boonsakan, Tanin Intragumtornchai, Jakrawadi Julamanee, Kanchana Chansung, Kanita Kayasut, Winyu Mitranun, Tawatchai Suwanban, Nongluk Kanitsap, Kitsada Wudhikarn, Pongsak Wannakrairot, Archrob Khuhapinant, Udomsak Bunworasate, Sanya Sukpanichnant, Rutchanid Pornvipavee
Publikováno v:
Hematological Oncology. 36:28-36
Systemic reports on the descriptive epidemiology of non-Hodgkin lymphoma (NHL) from Southeast Asia are scarce. A nationwide multi-institutional registry was conducted to compare the histopathology, clinical features, and survival of Thai adult patien
Autor:
Archrob Khuhapinant, Pimjai Niparuck, Lalita Norasetthada, Kanchana Chansung, Tawatchai Suwanban, Nonglak Kanitsap, Peerapon Wong, Tanin Intragumtornchai, Somchai Wongkhantee, Arnuparp Lekhakula, Tontanai Numbenjapon, Weerasak Nawarawong, Supachai Ekwattanakit, Pannee Praditsuktavorn, Jakrawadee Julamanee, Nisa Makruasri, Kitsada Wudhikarn, Udomsak Bunworasate, Suporn Chuncharunee, Chittima Sirijerachai, Kannadit Prayongratana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72e4ef3debcee30e0de8859c18cdd3c1
https://doi.org/10.1002/hon.2687/v2/response1
https://doi.org/10.1002/hon.2687/v2/response1
Autor:
Tanin Intragumtornchai, Kanchana Chansung, Kitsada Wudhikarn, Arnuparp Lekhakula, Udomsak Bunworasate, Archrob Khuhapinant, Jakrawadee Julamanee, Nisa Makruasri, Lalita Norasetthada, Pimjai Niparuck, Kannadit Prayongratana, Supachai Ekwattanakit, Somchai Wongkhantee, Tontanai Numbenjapon, Weerasak Nawarawong, Tawatchai Suwanban, Suporn Chuncharunee, Chittima Sirijerachai, Peerapon Wong, Pannee Praditsuktavorn, Nonglak Kanitsap
Publikováno v:
Hematological oncologyREFERENCES. 37(5)
Event free survival at 24 months (EFS24) has been described as a powerful predictor for outcome in several subtypes of B cell lymphoma. However, it was limitedly described in T cell lymphoma. We explored the implication of EFS24 as a predictor marker
Autor:
Jakrawadee Julamanee, Pimjai Niparuck, Archrob Khuhapinant, Tanin Intragumtornchai, Nisa Makruasi, Arnuparp Lekhakula, Kanchana Chansung, Kannadit Prayongratana, Somchai Wongkhantee, Tontanai Numbenjapon, Lalita Norasetthada, Weerasak Nawarawong, Tawatchai Suwanban, Kitsada Wudhikarn, Nonglak Kanitsap, Udomsak Bunworasate, Supachai Ekwattanakit, Peerapon Wong, Pannee Praditsuktavorn, Suporn Chuncharunee, Chittima Sirijerachai
Publikováno v:
Annals of Hematology. 96:57-64
Secondary central nervous system (CNS) relapse is a serious and fatal complication of diffuse large B cell lymphoma (DLBCL). Data on secondary CNS (SCNS) relapse were mostly obtained from western countries with limited data from developing countries.
Autor:
Tanin Intragumtornchai, Pimjai Niparuck, Kitsada Wudhikarn, Udomsak Bunworasate, Nonglak Kanitsap, Nisa Makruasi, Pannee Praditsuktavorn, Tawatchai Suwanban, Supachai Ekwattanakit, Somchai Wongkhantee, Tontanai Numbenjapon, Weerasak Nawarawong, Kannadit Prayongratana, Peerapon Wong, Suporn Chuncharunee, Chittima Sirijerachai, Jakrawadee Julamanee, Lalita Norasetthada, Kanchana Chansung, Arnuparp Lekhakula, Archrob Khuhapinant
Publikováno v:
Blood. 134:2128-2128
Introduction: Stage I disease represents a minor subset of aggressive Non-Hodgkin Lymphoma (NHL) accounting around 10%. Overall prognosis is generally good but varied upon different histologic subtypes and topographic presentation. Herein, we describ
Autor:
Tawatchai Suwanban, Somchai Wongkhantee, Tontanai Numbenjapon, Weerasak Nawarawong, Tanin Intragumtornchai, Nisa Makruasi, Suporn Chancharunee, Chittima Sirijerachai, K. Chansung, C. Laoruangroj, Peerapon Wong, Kitsada Wudhikarn, Udomsak Bunworasate, Nonglak Kanitsap, Jakrawadee Julamanee, Supachai Ekwattanakit, Archrob Khuhapinant, Lalita Norasetthada, Arnuparp Lekhakula, Pimjai Niparuck, Pannee Praditsuktavorn
Publikováno v:
Hematological Oncology. 37:277-278